Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial
BPC-157 (Body Protective Compound) is a peptide originally isolated from human gastric juice
While traditional pills often fail because of digestive breakdown, advanced delivery methods like liposomal technology have changed the landscape
Side effect comparison: Nausea: Similar rates between the two compounds Vomiting: Cagrilintide significantly lower (OR 0.38) Diarrhea: Comparable rates Constipation: Similar Injection site reactions: Cagrilintide substantially higher Discontinuation due to AEs: Cagrilintide much lower (1% vs approximately 5-7%) The takeaway: if vomiting was your main problem on semaglutide, cagrilintide may be worth exploring
Over about 84 weeks, people taking CagriSema lost around 23% of their body weight, while those on Zepbound lost about 25.5% at its highest dose
Professional Manufacturer: We are a direct professional manufacturer offering competitive pricing